Sensex, Nifty to open lower; Tata Motors, RIL, IndiGo, NTPC, Biocon, Cipla shares in focus
The Sensex and Nifty are poised to open lower on Wednesday, in line with global equities amid concerns about aggressive interest rate hikes from the U.S. Federal Reserve.
Biocon says 'all product approvals are legitimate' in bribery case for insulin approval
CBI says the accused was trying to exert undue influence on officers of CDSCO to waive the Phase III trial of "Insulin Aspart Injection".
Covid-19 put spotlight on vaccines, diagnostics: Mazumdar-Shaw
Resurgence of interest and new technologies bring a huge opportunity for the vaccine development field, says Biocon CMD Kiran Mazumdar-Shaw.
Biocon developing 20 biosimilar products for global markets
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
Nykaa’s Falguni now richer than Havells, Marico, Eicher and Biocon owners
FSN E-Commerce breaks into top 100 mcap club with a valuation of $14 billion.
VIDEO - Future is bio-pharma: Kiran Mazumdar-Shaw
Biocon's executive chairperson Dr Kiran Mazumdar Shaw, calls for a PLI scheme specially focused on incentivising biopharma investment.
VIDEO - Shot in the foot with pharma price control: Shaw
The executive chairperson of Biocon exhorts the government to revisit pharma price controls from a global perspective, in order to incentivise local manufacturing in the industry.
Covid-19 is an endemic, not pandemic: Mazumdar-Shaw
Kiran Mazumdar-Shaw, the Biocon chief, feels hospitalisation and not infection count matters in the fight against Coronavirus.
Mix and match vaccines, says Kiran Mazumdar-Shaw
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.